Histopathological Features of Brain Arteriovenous Malformations in Japanese Patients

Yulius Hermanto,1 Yasushi Takagi,1 Kazumichi Yoshida,1 Akira Ishii,1 Takayuki Kikuchi,1 Takeshi Funaki,1 Yohei Mineharu,1 and Susumu Miyamoto1

1Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto

Abstract
Clinical features of high risk brain arteriovenous malformations (BAVMs) are well characterized. However, pathological evidences about the differences that are possessed by high risk patients are still lacking. We reviewed archived routine hematoxylin-eosin specimens from a total of 54 surgical treated BAVMs. The histopathological features in nidus were semi-quantitatively analyzed. We obtained the pathological differences of BAVMs nidus between several clinical features. Among the analyzed pathological features, the significant differences were observed in degree of venous enlargement and intimal hyperplasia. Juvenile, female, diffuse nidus, high Spetzler-Martin grade, and low flow patients had a lesser degree of those parameters compared to adult, male, compact nidus, low Spetzler-Martin grade and high flow patients. High risk profiles of BAVMs patients were well-reflected in the nidus pathology. Therefore, juvenile, female, diffuse nidus, and low flow in Japanese BAVMs patients might have different vascular remodeling process that predispose to higher tendency of hemorrhage.

Key words: arteriovenous malformations, histopathological study, clinical features, nidus

Introduction
Brain arteriovenous malformations (BAVMs) comprise tangles of abnormally developed arteries and veins without intervening capillaries.1) As a consequence, an abnormal shunting of arteries and veins occurs and results in high-pressure vascular channels that are at a risk of rupturing, often with catastrophic results.2) Therefore, appropriate management is necessary to reduce lifetime risk of morbidity and mortality of BAVMs.

The BAVMs always provide challenge for neurosurgeons, as the risk of procedure may outweigh the benefits.3) Spetzler-Martin grading has been widely used for determining surgical-related morbidity,4) subsequently Lawton et al.5) proposed supplementary grading for determining surgical morbidity of BAVMs. However, high risk patients such as history of hemorrhage,6–8) young age,9,10) deep venous drainage,6,11,12) and female10) might need more aggressive modalities due to lifetime risk of hemorrhage. Despite high risk patients are well-identified, direct pathological evidences about the differences that are possessed by high risk patients are still lacking.

Materials and Methods

I. Patient population
A total of 54 specimens were obtained from the surgical treatment of BAVMs of Japanese patients at Kyoto University Hospital with standard indications. Clinical data of the patients are summarized in Table 1.

II. Sample preparation
All specimens were fixed in 10% formalin overnight and embedded in paraffin the next day. The specimens were stored at room temperature. Specimens were sliced into multiple and sequential 6-μm thick sections, deparaffinized in xylene, rehydrated, and then used for histological studies. All specimens were stained with hematoxylin-eosin and observed with a BX51 microscope (Olympus Optical Co., Ltd., Tokyo).

III. Assessment of infiltrating cells
We searched the focus of inflammation in the nidus by using low power magnification. Then, the
number of infiltrating cells was observed by using high power magnification on three adjacent fields. The average numbers of infiltrating cells were classified semi-quantitatively as follows: less than 20 (mild), 20–40 (moderate), and more than 40 (severe).

IV. Assessment of intimal hyperplasia

The thickest tunica intima of the vein in hematoxylin-eosin stained samples was recorded. The findings were classified semi-quantitatively as follows: less than 100 μm (mild), 100–200 μm (moderate), and more than 200 μm (severe).

V. Assessment of microvessel accumulation

Initially, we identified the highest vascular density region in the nidus of the hematoxylin-eosin stained samples by using low power magnification, then measured the number of microvessels (< 100 μm) by using high power magnification (10× objective). The findings were classified semi-quantitatively as follows: less than 10 (mild), 10–20 (moderate), and more than 20 (severe).

VI. Assessment of venous enlargement

We carefully determined the largest venous diameter in hematoxylin-eosin stained samples. The findings were classified semi-quantitatively as follows: less than 1 mm (mild), 1–2 mm (moderate), and more than 2 mm (severe).

VII. Statistical analysis

The results of all histopathological studies were expressed as the mean ± standard deviation. Statistical analysis was performed with SofaStats 1.4.3 (Paton-Simpson & Associates, Auckland, New Zealand). Clinical data including age, sex, occurrence of hemorrhage, seizure, velocity, size of nidus, and pre-operative embolization were analyzed along with histological data. P values less than 0.05 were considered statistically significant.

Results

In the present study, we assessed the pathological features in the BAVMs nidus particularly focusing on infiltrating cells, intimal hyperplasia, microvessels accumulation, and venous enlargement (Fig. 1). Among the assessed parameters, only intimal hyperplasia and venous enlargement were predominantly affected by the clinical variables.

We identified several significant clinical variables highly influential for nidal pathology: ages, nidus diffuseness, sex, Spetzler-Martin grade, and nidal velocity (Table 2).

Discussion

The present study revealed that intimal hyperplasia and venous enlargement in BAVMs nidus pathologically were the differentiating factors of clinical profiles of BAVMs patients. Our result might indirectly the vascular remodeling process was regulated differently between certain patients profiles. Younger age of onset and female patients tended to have the thinner intima and smaller drainer, although hemorrhage presentation was not increased in the aforementioned group, the condition might predispose for further hemorrhage if untreated. In line with this study, our previous report indicated that children and female patients had higher risk for subsequent hemorrhage after initial hemorrhage.10)
Apparently, there is inconsistency in patients age and sex as predictors for hemorrhage in BAVMs.\textsuperscript{12,13} It is noteworthy, racial background in the clinical series might contribute to those differences. At least, two reports from Scandinavian region also indicated that younger age\textsuperscript{7,14} and female\textsuperscript{14} are more prone to future hemorrhage. Furthermore, the fertile female might get into the pregnancy thus important consideration is needed in this management of this group.\textsuperscript{15}

In this study, angiographically obtained clinical profiles such as nidal diffuseness, velocity, and Spetzler-Martin grade were influential for the intimal hyperplasia and venous enlargement. Diffuse nidus, low flow, and higher Spetzler-Martin grade were observed to have thinner intimal hyperplasia and smaller drainer. We defined low flow BAVMs as slower transition from arterial to venous phase in angiography, this indirectly reflects the venous hypertension (Y.T. and S.M.). Those aforementioned conditions were highly consistent as hemorrhagic predictors in BAVMs.\textsuperscript{6,7,10–14,16} Furthermore, in our series, higher proportion of hemorrhage presentation was obtained in low flow patients (83.3\% in low flow patients, 33.3\% in high flow patients). Therefore, we assumed that hemodynamic properties of BAVMs have a highly prominent role in vascular remodeling process in nidus.

To our surprise, infiltrating cells were not influenced by clinical profiles. The presence of inflammation in BAVMs nidus is well noticed,\textsuperscript{17} we had reported the activation of NF-kappa B and STAT3 in the BAVMs.\textsuperscript{18,19} It is noteworthy, the precised contribution of inflammation in BAVMs pathobiology remains elusive. Moreover, our semi-quantitative scoring might also contribute to the result.

The highly angiogenic environment of BAVMs nidus is well documented, abnormality in VEGF,\textsuperscript{20,21} Tie-2,\textsuperscript{20,21} and HIF-1α\textsuperscript{22} might contribute to BAVMs pathobiology. In the present study, the highly angiogenic environment was well reflected through microvessels accumulation in the nidus; however the difference was not detectable between clinical variables. We assumed the abnormal angiogenesis is a common feature of BAVMs, thus insensitive to differentiate.

Fig. 1 Hematoxylin-eosin staining of human brain arteriovenous malformations tissues. A: profound venous enlargement is well identified. B: Intimal hyperplasia is found in the venous wall. C: Infiltrating cells can be observed in the vascular walls and perivascular tissues. D: Microvessels accumulation with profound infiltrating cells at the enlarged and hyperplastic vein can be observed. Scale bars: 300 μm.
the high risk patients. Of note, our semi-quantitative scoring might also contribute to the result.

**Conclusion**

In this study, the intimal hyperplasia and venous enlargement were distinctly influenced by clinical features. Younger age and female patients, as well as angiographical features of diffuse nidus, low flow, and high Spetzler-Martin grade possessed thinner intimal hyperplasia and smaller drainer. Those conditions might predispose high risk patients to higher tendency of hemorrhage in Japanese patients. Future investigation is necessary to elucidate the underlying mechanism.

**Conflicts of Interest Disclosure**

The authors declare that there is no conflict of interest.

**References**

1) Takagi Y, Kikuta K, Sadamasa N, Nozaki K, Hashimoto N: Proliferative activity through extracellular signal-regulated kinase of smooth muscle cells in vascular walls of cerebral arteriovenous malformations. *Neurosurgery* 58: 740–748; discussion 740–748, 2006

2) Shin M, Kawahara N, Maruyama K, Tago M, Ueki K, Kirino T: Risk of hemorrhage from an arteriovenous malformation confirmed to have been obliterated on angiography after stereotactic radiosurgery. *J Neurosurg* 102: 842–846, 2005

3) Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR, Al-Shahi Salman R, Vicaut E, Young WL, Houdart E, Cordonnier C, Stefani MA, Hartmann A, von Kummer R, Biondi A, Berkefeld J, Klijn CJ, Harkness K, Libman R, Barreau X, Moskowitz AJ; International ARUBA Investigators: Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. *Lancet* 383: 614–621, 2014

4) Spetzler RF, Martin NA: A proposed grading system for arteriovenous malformations. *J Neurosurg* 65: 476–483, 1986

5) Lawton MT, Kim H, McCulloch CE, Mikhak B, Young WL: A supplementary grading scale for selecting patients with brain arteriovenous malformations for surgery. *Neurosurgery* 66: 702–713; discussion 713, 2010

---

**Table 2  Summary of statistical analysis for histopathological features**

| Clinical manifestations | Histological characteristics |
|-------------------------|------------------------------|
|                         | Infiltrating cells | Intimal hyperplasia | Microvessels accumulation | Venous enlargement |
| Age                     |                 |                   |                          |                  |
| ≥ 20 years              | 1.95 ± 0.79     | 2.56 ± 0.72*      | 2.10 ± 0.82              | 2.90 ± 0.38*     |
| < 20 years              | 1.93 ± 0.96     | 1.60 ± 0.74       | 2.27 ± 0.80              | 2.27 ± 0.70      |
| Hemorrhage presentation |                 |                   |                          |                  |
| Yes                     | 2.04 ± 0.90     | 2.11 ± 0.89       | 2.33 ± 0.73              | 2.63 ± 0.56      |
| No                      | 1.85 ± 0.77     | 2.48 ± 0.75       | 1.96 ± 0.85              | 2.81 ± 0.56      |
| Nidal diffuseness       |                 |                   |                          |                  |
| Compact                 | 1.93 ± 0.82     | 2.44 ± 0.78*      | 2.15 ± 0.79              | 2.80 ± 0.51      |
| Diffuse                 | 2.00 ± 0.91     | 1.85 ± 0.90       | 2.15 ± 0.90              | 2.46 ± 0.66      |
| Pre-operative embolization |             |                   |                          |                  |
| Yes                     | 1.90 ± 0.88     | 2.00 ± 0.82       | 2.00 ± 0.82              | 2.70 ± 0.48      |
| No                      | 1.95 ± 0.83     | 2.36 ± 0.84       | 2.18 ± 0.81              | 2.73 ± 0.59      |
| Seizure presentation    |                 |                   |                          |                  |
| Yes                     | 1.86 ± 0.86     | 2.29 ± 0.83       | 2.00 ± 0.88              | 2.64 ± 0.74      |
| No                      | 1.98 ± 0.83     | 2.30 ± 0.85       | 2.20 ± 0.79              | 2.75 ± 0.49      |
| Sex                     |                 |                   |                          |                  |
| Male                    | 1.79 ± 0.77     | 2.59 ± 0.78*      | 2.10 ± 0.82              | 2.86 ± 0.44      |
| Female                  | 2.12 ± 0.88     | 1.96 ± 0.79       | 2.20 ± 0.82              | 2.56 ± 0.65      |
| Spetzler-Martin Grade   |                 |                   |                          |                  |
| < 3                     | 2.03 ± 0.84     | 2.46 ± 0.76*      | 2.23 ± 0.81              | 2.79 ± 0.52      |
| ≥ 3                     | 1.77 ± 0.83     | 1.77 ± 0.93       | 2.00 ± 0.82              | 2.46 ± 0.66      |
| Velocity                |                 |                   |                          |                  |
| High                    | 2.06 ± 0.83     | 2.61 ± 0.60*      | 2.11 ± 0.85              | 2.86 ± 0.49*     |
| Low                     | 1.72 ± 0.83     | 1.67 ± 0.91       | 2.22 ± 0.73              | 2.44 ± 0.62      |

* indicates $p < 0.05$, statistical test performed with Mann-Whitney U test.
6) Pollock BE, Flickinger JC, Lunsford LD, Bissonette DJ, Kondziolka D: Factors that predict the bleeding risk of cerebral arteriovenous malformations. Stroke 27: 1–6, 1996

7) Hernesniemi JA, Dashti R, Juvela S, Väärt K, Niemelä M, Laakso A: Natural history of brain arteriovenous malformations: a long-term follow-up study of risk of hemorrhage in 238 patients. Neurosurgery 63: 823–829; discussion 829–831, 2008

8) Laakso A, Dashti R, Juvela S, Isarakul P, Niemelä M, Hernesniemi J: Risk of hemorrhage in patients with untreated Spetzler-Martin grade IV and V arteriovenous malformations: a long-term follow-up study in 63 patients. Neurosurgery 68: 372–377; discussion 378, 2011

9) Darsaut TE, Guzman R, Marcellus ML, Edwards MS, Tian L, Do HM, Chang SD, Levy RP, Adler JR, Marks MP, Steinberg GK: Management of pediatric intracranial arteriovenous malformations: experience with multimodality therapy. Neurosurgery 69: 540–556; discussion 556, 2011

10) Yamada S, Takagi Y, Nozaki K, Kikuta K, Hashimoto N: Risk factors for subsequent hemorrhage in patients with cerebral arteriovenous malformations. J Neurosurg 107: 965–972, 2007

11) Kader A, Young WL, Pile-Spellman J, Mast H, Sciaccia RR, Mohr JP, Stein BM: The influence of hemodynamic and anatomic factors on hemorrhage from cerebral arteriovenous malformations. Neurosurgery 34: 801–807; discussion 807–808, 1994

12) Stapf C, Mast H, Sciaccia RR, Choi JH, Khaw AV, Connolly ES, Pile-Spellman J, Mohr JP: Predictors of hemorrhage in patients with untreated brain arteriovenous malformation. Neurology 66: 1350–1355, 2006

13) Kim H, Al-Shahi Salman R, McCulloch CE, Stapf C, Young WL; MARS Coinvestigators: Untreated brain arteriovenous malformation: patient-level meta-analysis of hemorrhage predictors. Neurology 83: 590–597, 2014

14) Karlsson B, Lindquist C, Johansson A, Steiner L: Annual risk for the first hemorrhage from untreated cerebral arteriovenous malformations. Minim Invasive Neurosurg 40: 40–46, 1997

15) Fukuda K, Hamano E, Nakajima N, Katsuragi S, Ikeda T, Takahashi JC, Miyamoto S, Iihara K: Pregnancy and delivery management in patients with cerebral arteriovenous malformation: a single-center experience. Neurol Med Chir (Tokyo) 53: 565–570, 2013

16) Al-Shahi R, Warlow C: A systematic review of the frequency and prognosis of arteriovenous malformations of the brain in adults. Brain 124: 1900–1926, 2001

17) Chen Y, Zhu W, Bollen AW, Lawton MT, Barbaro NM, Dowd CF, Hashimoto T, Yang GY, Young WL: Evidence of inflammatory cell involvement in brain arteriovenous malformations. Neurosurgery 62: 1340–1349; discussion 1349–1350, 2008

18) Aziz MM, Takagi Y, Hashimoto T, Miyamoto S: Expression and activation of STAT family proteins in cerebral arteriovenous malformations. World Neurosurg 78: 487–497, 2012

19) Aziz MM, Takagi Y, Hashimoto T, Miyamoto S: Activation of nuclear factor κB in cerebral arteriovenous malformations. Neurosurgery 67: 1669–1679; discussion 1679–1680, 2010

20) Hashimoto T, Emala CW, Joshi S, Mesa-Tejada R, Quick CM, Feng L, Libow A, Marchuk DA, Young WL: Abnormal pattern of Tie-2 and vascular endothelial growth factor receptor expression in human cerebral arteriovenous malformations. Neurosurgery 47: 910–918; discussion 918–919, 2000

21) Hashimoto T, Lawton MT, Wen G, Yang GY, Chaly T Jr, Stewart CL, Dressman HK, Barbaro NM, Marchuk DA, Young WL: Gene microarray analysis of human brain arteriovenous malformations. Neurosurgery 54: 410–423; discussion 423–425, 2004

22) Takagi Y, Kikuta K, Moriwaki T, Aoki T, Nozaki K, Hashimoto N, Miyamoto S: Expression of thioredoxin-1 and hypoxia inducible factor-1α in cerebral arteriovenous malformations: possible role of redox regulatory factor in neoangiogenic property. Surg Neurol Int 2: 61, 2011

Address reprint requests to: Yasushi Takagi, MD, PhD, Department of Neurosurgery, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Sakyo, Kyoto, Japan. e-mail: ytakagi@kuhp.kyoto-u.ac.jp